Medicare to boost payment for certain diagnostic imaging agents
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
Diagnostic Imaging Radiopharmaceuticals 
Targeted radiopharmaceuticals offer new hope for longer 'healthspans'
AuntMinnie
MARCH 15, 2024
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
Join 5,000
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
CMS proposes issuing separate payment for diagnostic radiopharmaceuticals in 2025
Radiology Business
JULY 12, 2024
For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.
CMS proposes new coverage for PET imaging agents
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Nuclear Medicine 
305
305 
Radiopharmaceutical firm Telix investing up to $171M to acquire portfolio of imaging agents
Radiology Business
NOVEMBER 20, 2024
The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.
Italian research team shows the way on sustainability
AuntMinnie
FEBRUARY 26, 2025
The new horizons of advanced imaging, especially in oncology, must increasingly consider not only diagnostic efficacy but also sustainability for patients, prize-winning researchers told ECR 2025 delegates. To mitigate these effects, low-energy imaging techniques should be prioritized without compromising diagnostic accuracy.
Bone Scan 130
130 
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
AuntMinnie
APRIL 4, 2024
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
CMS Adjusts Nuclear Medicine Reimbursement Policy, Expanding Access to Life-Saving Scans
Imaging Technology
NOVEMBER 7, 2024
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.
GE HealthCare to launch Flyrcado injection in U.S.
AuntMinnie
MARCH 27, 2025
Flyrcadois a unit-dose PET myocardial perfusion imaging (MPI) agent intended for patients with known or suspected coronary artery disease. Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. The company received approval from the U.S. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
Healthcare 130
130 
Generative AI, radiologist shortages feature in 2024 Minnies
AuntMinnie
NOVEMBER 12, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. Given the extensive array of sequences and techniques employed in clinical imaging, we must address the inherent challenges associated with each," he noted.
Radiologist 360
360 
The rise of theranostics: Part 5 -- Advice from center administrators
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
Nuclear Medicine 264
264 
The rise of theranostics: Part 3 -- What is a theranostics center?
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Nuclear Medicine 264
264 
ASTRO: Lu-177 dotatate shows promise for treating meningioma patients
AuntMinnie
SEPTEMBER 30, 2024
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Diagnostic Imaging
NOVEMBER 15, 2024
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Meet the Minnies 2024 finalists
AuntMinnie
OCTOBER 25, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. 7-tesla MRI gets us closer in imaging to our pathology colleagues, and offers many new possibilities for better treatment," he said. Perry Pickhardt, MD. He served in the U.S.
Nuclear Medicine 358
358 
New CMS plan adds Medicare coverage of PET imaging agents
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Medicare 130
130 
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer
Imaging Technology
JULY 9, 2024
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
Diagnostic 105
105 
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
Diagnostic 105
105 
Radiopharmaceutical Diagnostics and Imaging Technologies
Open Medscience
FEBRUARY 28, 2024
Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine. The post Radiopharmaceutical Diagnostics and Imaging Technologies appeared first on Open Medscience.
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
Imaging Technology
JULY 25, 2023
The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.
Imaging societies' reactions mixed on finalized MPFS, HOPPS rules
AuntMinnie
NOVEMBER 4, 2024
providers and the entire cardiac imaging community,” said Ahmad Slim, MD, chair of the SCCT Health Policy and Practice Committee. With this rule in place, the CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630. “This is a huge win for U.S.
SNMMI names winners of 2025 legislative advocacy award
AuntMinnie
MARCH 26, 2025
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented its 2025 Legislative Champion Award to Representatives Neal Dunn, MD, and Ami Bera, MD. Centers for Medicare and Medicaid (CMS) to update the Hospital Outpatient Prospective Payment System (HOPPS) in 2025 by unbundling radiopharmaceuticals.
Nuclear Medicine 130
130 
FCH-PET/CT superior to MIBI-SPECT/CT for guiding parathyroid surgery
AuntMinnie
JUNE 20, 2024
F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred. The full study is available here.
The rise of theranostics: Part 1 -- Gaining momentum
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Nuclear Medicine 306
306 
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
Imaging Technology
JANUARY 5, 2024
The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. It can also be used for beta-particle targeted RPT using copper isotopes.
FDA approves new PET tracer for prostate cancer imaging
AuntMinnie
MAY 30, 2023
Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Gallium Radiopharmaceuticals in Medical Imaging
Open Medscience
NOVEMBER 17, 2023
Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.
RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers
Imaging Technology
SEPTEMBER 20, 2023
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
Pharmaceutical 105
105 
The Transformative Power of Radiopharmaceuticals in Diagnostics
Open Medscience
AUGUST 11, 2024
Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.
Nuclear cardiology could face cuts in 2025
AuntMinnie
SEPTEMBER 25, 2024
Centers for Medicare and Medicaid Services (CMS) to “unbundle” payments for diagnostic radiopharmaceuticals from the cost of nuclear medicine tests, cardiac SPECT procedures may get the short end of the stick, said Lawrence Phillips, MD, of NYU Langone Health in New York City, in an interview with AuntMinnie.com.
First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
Imaging Technology
JULY 11, 2023
The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging
Open Medscience
NOVEMBER 12, 2023
Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications. The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience.
FDA fast-tracks Clarity’s prostate cancer treatment
AuntMinnie
FEBRUARY 19, 2025
Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnostic imaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.
Evidence grows for use of amyloid PET in China
AuntMinnie
FEBRUARY 12, 2024
Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University.
PET Scan 262
262 
New Guidance for Amyloid and Tau PET Imaging Released
Imaging Technology
JANUARY 30, 2025
30, 2025 Earlier this month, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,
Unlocking the potential of imaging in Alzheimer’s disease care
AuntMinnie
JANUARY 19, 2024
The promise of imaging One challenge is that advances in Alzheimer’s care can only help people if they are reaching the right patients at the right time in their patient journey. More accurate diagnostic and monitoring tools can also help manage the high cost of new therapies by preventing the misuse of expensive treatments.
Disease 130
130 
Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent
Imaging Technology
FEBRUARY 5, 2025
SPE is not well visualized with current non-invasive imaging tools (ultrasound and MRI) and definitive diagnosis requires laparoscopy. The planned Phase III study will compare the findings from women undergoing laparoscopic surgery for endometriosis with imaging using 99m Tc-maraciclatide and SPECT-CT prior to surgery.
Healthcare 52
52 
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,
Diagnostic 97
97 
Zirconium Radiopharmaceuticals in Nuclear Medicine
Open Medscience
JANUARY 1, 2024
Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.
GE HealthCare to launch Flyrcado injection in U.S.
AuntMinnie
MARCH 27, 2025
Flyrcadois a unit-dose PET myocardial perfusion imaging (MPI) agent intended for patients with known or suspected coronary artery disease. Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. The company received approval from the U.S. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
Healthcare 147
147 
FIND Act reintroduced in U.S. Senate
AuntMinnie
MAY 17, 2023
The Facilitating Access to Innovative Diagnostics (FIND) Act -- legislatio. Read more on AuntMinnie.com Related Reading: FIND Act reintroduced in Congress MITA hails radiopharmaceutical legislation SNMMI supports new legislation to fix PET payment policy Molecular imaging saw wins, losses over past year
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.
Diagnostic 98
98 
Let's personalize your content